(Q44884813)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

title

Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

author name string

Laura Corvatta

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Monica Marconi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Lara Malerba

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Anna Mele

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Attilio Olivieri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Marino Brunori

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Massimo Catarini

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Marco Candela

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Debora Capelli

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Mauro Montanari

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Serena Rupoli

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

Pietro Leoni

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

publication date

1 June 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Haematology

28 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

volume

72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

page(s)

403-409

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

28 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15128418%20AND%20SRC:MED&resulttype=core&format=json

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

28 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00238.X

Thalidomide and dexamethasone combination for refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00238.X

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00238.X

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00238.X

Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00238.X

Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00238.X

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00238.X

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00238.X

The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00238.X

Thalidomide-induced neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00238.X

Thalidomide-associated hepatitis: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00238.X

Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2004.00238.X